Treatment of Opioid Use Disorder: Waiver Qualifying - Phoenix, AZ - Friday, February 19, 2021

4 (1 vote)

  • Register
    • Non-Member - $25
    • Regular Member - $25
    • Retired - $25
    • Early Career Physician - $25
    • Resident - $25
    • Student - $25
    • Associate - $25
    • ASAM Staff - Free!
    • International Member - $25
    • Emeritus Member - $25
    • Provisional Member - $25
    • Fellow Member - $25
    • Honorary Member - $25
    • CRT Member - $25
image

Host: University of Arizona College of Medicine Phoenix

Date: Friday, February 19, 2021 | 2pm – 6pm (MST)

 Live Virtual Course

Online Portion Due: Thursday, February 18, 2021


This course is offered in partnership with the American College of Obstetricians and Gynecologists (ACOG). The curriculum for this course has been specifically designed for women's health providers.

Overview

Welcome to The ASAM Treatment of Opioid Use Disorder Course online access. This course covers all medications and treatments for opioid use disorder, and provides the required education needed to obtain the waiver to prescribe buprenorphine. ASAM is an approved provider by CSAT/SAMHSA of DATA 2000 training. This is an 8-hour blended course combining 4 hours of online learning followed by 4 hours of live in person or via live webinar learning. The live in person or via live webinar portion of the course builds off content delivered in the online portion. Course faculty are expecting learners to complete the online portion before attending the live in person or via live webinar portion. You must complete both portions to receive credit for the course. 

Getting Started

To begin the online portion of the course, please log-in to your left and locate the box that says "View Course." If you do not know your password, or you have forgotten it, select "Forgot Password" and you will be emailed a link to reset your password.  If you have any questions, please contact education@ASAM.org.

Learning Objectives

  1. Identify the importance of screening for substance use disorders
  2. Describe the mechanism of opioid withdrawal
  3. Discuss options to treat opioid withdrawal
  4. Explain the safety and efficacy of buprenorphine to treat opioid use disorder
  5. Explain the safety of medications in antepartum, postpartum, and breastfeeding period
  6. Describe how to start a patient (induction) on buprenorphine in an office-based setting
  7. Discuss successful non-pharmacological ways to treat Neonatal Abstinence Syndrome

Overall Objective

Apply for a waiver to prescribe buprenorphine to patients with opioid use disorder.

Key:

Complete
Failed
Available
Locked
Ob-Gyn Pre-Course Survey
4 Questions
View Course
Begin self-paced component package.
Begin self-paced component package. Complete Module 1 and Module 2.
Complete Online Portion Evaluation
17 Questions
17 Questions Please complete the evaluation to claim CME.
Live Webinar
02/19/2021 at 4:00 PM (EST)   |  270 minutes
02/19/2021 at 4:00 PM (EST)   |  270 minutes Live Webinar begins at 2pm MST (4:00 pm ET) Register in advance for this webinar using the link below.
Ob-Gyn Post-Course Survey
4 Questions
Complete Live Portion Evaluation
17 Questions
17 Questions Please complete the evaluation to claim CME.
Download CME Certificate
Up to 8.00 medical credits available  |  Certificate available
Up to 8.00 medical credits available  |  Certificate available This session has been approved for 8 AMA PRA Category 1 Credits. Participants should claim only the credits commensurate with the extent of their participation in the activity.

Target Audience

  1. Physicians, Nurse Practitioners, Physician Assistants, Certified Nurse Midwives, Certified Registered Nurse Anesthetists, and Clinical Nurse Specialists who wish to obtain a waiver to prescribe buprenorphine in an office-based setting for opioid use disorder.
  2. Clinicians and healthcare team members working with physicians who prescribe buprenorphine in office-based treatment of opioid use disorder.

Maria Manriquez

MD, FACOG

Maria Manriquez, M.D., FACOG is a University of Arizona College of Medicine Alumnus and currently directs the Pipeline Admissions and UMG Pain and Addition Curriculum at the University of Arizona College of Medicine Phoenix.  Dr. Manriquez brings vast experience in program direction that spans undergraduate education, medical education, graduate and continued medical education. Her service includes vice chair then chair of the Arizona section of American College of Obstetricians and Gynecologist (ACOG). She has served as At-Large Fellow for District VIII on the advisory council for ACOG. Dr. Manriquez currently sits on the Council of Resident Education and Gynecology (CREOG) and is the CREOG program chair. Dr Manriquez is one of two ACOG representatives to the AAMC CFAS.

Dr. Manriquez was the principle investigator for a large CMS grant, awarded to Maricopa Integrated Health Systems (MIHS), aimed at investigating innovations in prenatal care models addressing preterm delivery rate, substance use disorders in pregnancy and care coordination. During Dr. Manriquez’s tenure at MIHS she was Associate Director of the Residency Program in OBGYN and was Vice Chair of the OBGYN department. Dr. Manriquez continues to maintain a clinical practice at MIHS focusing on substance use- disorders in pregnancy. She developed and directs the Pathway Scholars Program, a program addressing diversity in the physician workforce. The program prepares underprivileged students for medical school through a yearlong curriculum designed to position them to thrive once they matriculate. 

Dr. Manriquez continues clinical practice focusing on substance use-disorders in pregnancy and parenting women at Banner University Medical Women’s Institute. Her research and advocacy focus are aimed at investigating innovations in prenatal care models addressing preterm delivery rate, substance use disorders in pregnancy and care coordination.  

Kirk Moberg

MD, PhD, FASAM

Dr. Kirk Moberg has practiced in the field of Addiction Medicine for 25 years.  He serves as Clinical Professor of Internal Medicine and Psychiatry at the University of Illinois College of Medicine.  Dr Moberg is board certified in Internal Medicine and Addiction Medicine and is a certified Medical Review Officer.

Credits and Disclosures


ACCME Accredited with Commendation

ACCME Accreditation Statement

The American Society of Addiction Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

AMA Credit Designation Statement

The American Society of Addiction Medicine designates this enduring activity for a maximum of 4 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The American Society of Addiction Medicine designates this live activity for a maximum of 4 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

NAADAC, the Association for Addiction Professionals

This activity has been approved by the American Society of Addiction Medicine, as a NAADAC Approved Education Provider, for educational credits. NAADAC Provider #295, ASAM is responsible for all aspects of the programming.

California Association for Drug/Alcohol Educators (CAADE)

This educational program is approved by CAADE: #CP40 999 1222

California Association of DUI Treatment Centers (CADTP)

This educational program is approved by CADTP: #205

California Consortium of Addiction Programs and Professionals (CCAPP)

This educational program is approved by CCAPP: #OS-20-330-1222

Continuing Education Credits (CEUs)

Non-physician participants will receive a certificate of attendance upon completion of the activity and an online evaluation confirming their participation. Participants should submit his/her certificate of attendance to their professional organization/institute.

Maintenance of Certification


American Board of Preventive Medicine (ABPM)

The American Board of Preventive Medicine (ABPM) has approved this activity for a maximum of 8 LLSA credits towards ABPM MOC Part II requirements.

American Board of Anesthesiology (ABA)

This activity contributes to the CME component of the American Board of Anesthesiology’s redesigned Maintenance of Certification in Anesthesiology TM (MOCA®) program, known as MOCA 2.0®.

American Board of Pediatrics (ABP)

Successful completion of this CME activity, which includes participation in the activity, with individual assessments of the participant and feedback to the participant, enables the participant to earn a maximum of 8 MOC points in the American Board of Pediatrics’ (ABP) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABP MOC credit.

American Board of Internal Medicine (ABIM)

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 8 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credits.

American Board of Surgery (ABS)

Successful completion of this CME activity, which includes participation in the evaluation component, enables the learner to earn credit toward the CME and/or Self-Assessment requirements of the American Board of Surgery’s Continuous Certification program. It is the CME activity provider's responsibility to submit learner completion information to ACCME for the purpose of granting ABS credit

American Board of Psychiatry and Neurology (ABPN)

Successful completion of this CME activity can be used to satisfy the American Board of Psychiatry and Neurology’s (ABPN) CME requirement for Maintenance of Certification program.

American Board of Addiction Medicine (ABAM)

Successful completion of this activity can be used to satisfy the American Board of Addiction Medicine (ABAM) for Tmoc as credits towards ABAM LLSA Part II requirements.

CME Reviewer and Disclosure Information


ASAM CME Committee Reviewer

Benjamin Bearnot, MD – Does Disclose

  • We The Village, Inc, Clinical Condition: Opioid Use Disorder, CRAFT support, Consultant/Advisory Board
  • Halcyon Health, Clinical Condition: Opioid Use Disorder, Recovery Coaching, Consultant/Advisory Board

Program Planning Committee, CME Committee, Medical Education Council (MEC), and Faculty Disclosure Information

In accordance with disclosure policies of ASAM and the ACCME, the effort is made to ensure balance, independence, objectivity, and scientific rigor in all CME activities. These policies include resolving all possible conflicts of interest for the Planning Committees, CME Committee, MEC, and Faculty. All activity Planning Committee members and Faculty have disclosed relevant financial relationship information. The ASAM CME Committee has reviewed these disclosures and determined that the relationships are not inappropriate in the context of their respective presentations and are not inconsistent with the educational goals and integrity of the activity.

Faculty and Planning Committee


Faculty Disclosure Information

Maria Manriquez, M.D., FACOG – No Relevant Financial Disclosures 

University of Arizona College of Medicine, Phoenix, Arizona

Edwin A. Salsitz, MD, DFASAM – No Relevant Financial Disclosures 

Mount Sinai Beth Israel, New York, NY 

Marian Currens, CRNP – Does Disclose 
University of Maryland Baltimore, Baltimore, MD

  • ASAM, Consultant/Advisory Board, Clinical Condition: MedNP ED

Debra Newman, PA-C, MPAS, MPH – No Relevant Financial Disclosures 
First Judicial District Court, Santa Fe, NM

Daniel P. Alford, MD, MPH, DFASAM - No Relevant Financial Disclosures 
Boston Medical School and Boston University School, Boston, MA

Corey Waller, MD, MS, DFASAM, FACEP – No Relevant Financial Disclosures 
Health Management Associates, Lansing, MI


Planning Committee Disclosure Information

Melissa Weimer, DO, MCR, FASAM – Does Disclose

  • Path CCM, Inc, Consultant/Advisory Board, Clinical Condition: SUD, Consultant/Advisory Board

Deanna Wilson, MD, MPH– No Relevant Financial Disclosures
Pittsburgh, PA

Alta DeRoo, MD, FASAM – Does Disclose

  • Indivior, Speaker honorarium
  • Alkermes, Speaker honorarium

Soraya Azari, MD – No Relevant Financial Disclosures
San Francisco, CA

Kristen Smith, DNP, FNP-C, AAHIVS – No Relevant Financial Disclosures
Atlanta, GA

Matt Tierney, NP, CNS – No Relevant Financial Disclosures
San Francisco, CA

Debra Newman, PA-C, MPAS, MPH – No Relevant Financial Disclosures
Santa Fe, NM

Edwin A. Salsitz, MD, DFASAM – No Relevant Financial Disclosures
New York, NY

How to Apply for a Waiver

Physicians

SAMHSA reviews waiver applications within 45 business days of receipt. If approved, you will receive a letter via email that confirms your waiver and includes your prescribing identification number.

Waiver applications are forwarded to the DEA. DEA regulations require your prescribing identification number to be included on all buprenorphine prescriptions for opioid dependency treatment, along with your regular DEA number.

If you have not received confirmation of receipt of your application, or if it has been more than 45 business days since submitting it, contact CSAT by email: infobuprenorphine@samhsa.hhs.gov or call 866.287.2728.

Other Approved Prescribers

Apply

NPs and PAs may upload copies of their training certificates on the Waiver Notification Form. NPs and PAs who have completed the 24 hours of required training may seek to obtain a DATA 2000 waiver for up to 30 patients by completing the Waiver Notification Form. Effective February 27, 2017, SAMHSA will only accept electronic submissions of the NOI.

These waiver applications are forwarded to the Drug Enforcement Administration (DEA), which will assign the NP or PA a special identification number. DEA regulations require this number to be included on all buprenorphine prescriptions for opioid dependency treatment, along with the NP’s or PA’s regular DEA registration number.

SAMHSA shall review waiver applications within 45 days of receipt. If approved, NPs and PAs will receive a letter via email that confirms their waiver and includes their prescribing identification number. 

Qualify

To qualify for a waiver to treat patients with Opioid Use Disorder, NPs and PAs must:

  • Be licensed under state law to prescribe schedule III, IV, or V medications for pain
  • Complete no less than 24 hours of appropriate education through a qualified provider
  • Through other training or experience, demonstrate the ability to treat and manage OUD
  • If required by state law, supervision or working in collaboration with a qualifying physician to prescribe medications for the treatment of OUD may be required.

Please ensure that your state regulations allow you to prescribe buprenorphine and other medications to treat OUD before you apply for the waiver.  Some states may have overriding state legislation that will prevent NPs from prescribing these medications even if Federal law allows it.

Overview of Legislation

Physicians

The Drug Abuse Treatment Act of 2000 (DATA 2000) specifies training is necessary for physicians to obtain a waiver to engage in office‐based treatment of opioid use disorders using drugs approved by the FDA on Schedules III, IV, and V. This course addresses those requirements using a curriculum approved by CSAT/SAMHSA and ASAM, who is one of the national organizations named in the DATA 2000 legislation as eligible to prepare and administer these courses.

Nurse Practitioners & Physician Assistants

On July 22, 2016, President Obama signed the Comprehensive Addiction and Recovery Act (CARA) into law. CARA authorizes qualified NPs and PAs to become waivered to prescribe buprenorphine in office-based settings for patients with Opioid Use Disorder (OUD) for a five-year period expiring in October 2021.    

To qualify, NPs and PAs must: 

  • Be licensed under state law to prescribe schedule III, IV, or V medications for pain  
  • Complete not less than 24 hours of appropriate education through a qualified provider
  • Through other training or experience, demonstrate the ability to treat and manage OUD  
  • If required by state law, be supervised or work in collaboration with a qualifying physician to prescribe medications for the treatment of OUD

HHS' announcement on November 16, 2016, enables NPs and PAs to immediately begin taking the 24 hours of required training. For the full HHS announcement, click here.

NPs and PAs can begin the training immediately by taking the 8-hour buprenorphine course ASAM currently offers or that other stakeholders offer (see below for more information). The remaining 16 hours will have to be completed with one training provider. ASAM is developing multiple 16-hour training course options and formats, including collaborations with: